Workshop on Enhancing Systemic Drug Delivery in Cancer
April 27-28, 2021, virtual meeting
(schedule in Eastern Standard Time)
Day 1 - April 27, 2021 10:30 am – 4:30 pm EDT |
|
| 10:30 - 10:45 EDT |
Opening Remarks and Workshop Logistics |
| SESSION 1: How to Deliver Cancer Therapies – Different Modalities, Different Needs | |
| 10:45 – 11:10 | Enhancing drug delivery in cancer prostate cancer William Dahut, MD, National Cancer Institute |
| 11:10 – 11:35 | RNA-based therapies toward improving cancer therapy Anil Sood, MD, MD Anderson Cancer Center |
| 11:35 – 12:00 | Targeted radionuclide therapies Neeta Pandit-Taskar, MD, Memorial Sloan Kettering Cancer Center |
| 12:00 - 12:30 | Discussion: Major delivery needs of existing therapies Moderator: Lalitha Shankar, MD, PhD, NCI/DCTD/CIP |
| 12:30 – 1:00 | LUNCH BREAK |
| SESSION 2: Drug Delivery Technologies | |
| 1:00 – 1:25 | Theranostics in delivering and monitoring cancer therapies Jordan Green, PhD, Johns Hopkins University |
| 1:25 – 1:50 | Delivery of RNA-based therapeutics Daniel Anderson, PhD, Mass. Institute of Technology |
| 1:50 – 2:15 | A new generation of multimodal targeted therapies for cancer Philip Low, PhD, Purdue University |
| 2:15 – 2:40 | Nano-chemotherapeutics in oncology: focus on liposome-based drugs, Alberto Gabizon, MD, PhD, Hebrew University-School of Medicine, Jerusalem, Israel |
| 2:40 – 3:05 | The answer to how we enhance systemic drug delivery in cancer treatment lies within the question Laurent Levy, PhD, Nanobiotix, Paris, France |
| 3:05 – 3:30 | Antibody-Drug Conjugates: current status and future directions John Lambert, PhD, John Lambert Consulting (formerly Immunogen Inc.) |
| 3:30 – 3:45 | BREAK |
| 3:45 – 4:30 | Discussion – How do we 'match' different treatment modalities and delivery technologies? Moderator: Stephan Stern, PhD, Frederick National Laboratory/NCL |
| 4:30 | Adjourn |
Day 2 - April 28, 2021 11:30 am – 2:30 pm EDT |
|
| 11:30 – 11:45 | Recap - Day 1 Outcomes |
| Innovation in Nano-delivery Constructs | |
| 11:45 – 12:10 | Samir Mitragotri, PhD, Harvard University |
| SESSION 3: Cancer Immunotherapy – Delivery and Treatment Outcomes | |
| 12:10 – 12:35 | Improving the efficacy of immune checkpoint inhibitors through combinations with radiotherapy Zachary Morris, MD, PhD, University of Wisconsin |
| 12:35 – 1:00 | Use of the silicasome platform for pancreatic cancer chemo-chemoimmunotherapy through the delivery of irinotecan and DACH-platinum Andre Nel, MD, PhD, UC Los Angeles |
| 1:00 – 1:25 | Enhancing CAR T cell delivery and cells as enhanced drug delivery vehicles Marcela Maus, MD, PhD, Mass. General Hospital |
| 1:25 – 1:50 | Enhancing cancer immunotherapy using nanomedicine approaches Darrell Irvine, PhD, Koch Institute, Mass. Institute of Technology |
| 1:5- – 2:30 | Final discussion: Which delivery technologies can be improved and where is the need for new innovations? Moderator: : Andre Nel, UC Los Angeles |
| 2:30 | Adjourn |